Clinical Trial

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer

Study acronym: COBP
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This prospective, single-arm study aims to investigate the efficacy and safety of pembrolizumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS locally advanced rectal cancer patients
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-10-18.
Status change: Not Yet Recruiting → Recruiting 2025-03-12
Trial Details
NCT Number NCT05585814
Lead Sponsor Shanghai Changzheng Hospital
Conditions Locally Advanced Colorectal Cancer
Enrollment 30 participants
Start Date 2023-05-01
Primary Completion 2024-10-01 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-14